A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma
Angiogenesis inhibitors have demonstrated significant clinical efficacy in mRCC. Pazopanib and sunitinib are both oral tyrosine kinase inhibitors primarily of VEGFR (-1, -2, and -3), PDGFR (-a and -b) and c-Kit. Pazopanib has a more selective kinase specificity profile compared to sunitinib and has demonstrated low rates of fatigue, hand foot syndrome and mucositis/stomatitis. There is an ongoing phase III head to head study of pazopanib vs. sunitinib in treatment naïve mRCC patients (pts). The outcomes of cancer therapy are traditionally evaluated using RECIST response and survival criteria. There is increasing emphasis on assessment of health related quality of life (HRQoL) particularly relevant to tolerability of agents. However, HRQoL questionnaires might not reflect the pt preference. Studies have shown an association between toxicity/intolerability and a response on HRQoL, suggesting that pt preference is a legitimate and useful endpoint.
No charity of our size with a specific focus on the elimination of death and suffering from kidney cancer has funded a greater number of research projects. This week, the ASCO Cancer Foundation presented us with an award to mark this commitment.
Get the latest news about kidney cancer from the 2010 Annual Meeting of the American Society of Clinical Oncology, in Chicago, Illinois.
Systemic Therapies in Advanced Renal Cell Cancer: Current Status by Christopher W. Ryan, M.D.
"We're delighted to share a wealth of new data on AS1413 and AS1411 at the ASCO meeting. Both drugs are approaching important milestones, with phase III data on AS1413 and phase IIb data on AS1411 due in the next 12 months. The latest findings provide further evidence of the unique potential of these novel approaches to cancer therapy."
Consumption of filtered and boiled coffee and the risk of incident cancer: A prospective cohort study
These findings demonstrate, for the first time, the potential relevance of brewing method in investigations of coffee consumption and cancer risk.
Abbott scientists and independent researchers will highlight the latest clinical trial data on four of Abbott's investigational oncology compounds at this year's American Society of Clinical Oncology (ASCO) Annual Meeting.
Glyn Edwards, CEO of Antisoma, said: "We're delighted to share a wealth of new data on AS1413 and AS1411 at the ASCO meeting. Both drugs are approaching important milestones, with phase III data on AS1413 and phase IIb data on AS1411 due in the next 12 months. The latest findings provide further evidence of the unique potential of these novel approaches to cancer therapy."
Abstracts published in the Annual Meeting Proceedings: late-Breaking Abstracts, and Clinical Review Abstracts will be available at 12:00 PM EDT on the date of their presentation at the 2010 ASCO Annual Meeting.
|NeonCRM by Neon One|